Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation

Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation

Item
http://www.wikidata.org/entity/Q34669637
Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity.Psoriatic cutaneous inflammation promotes human monocyte differentiation into active osteoclasts, facilitating bone damage.Bococizumab for the treatment of hypercholesterolaemia.Clinical utility of therapeutic drug monitoring in biological disease modifying anti-rheumatic drug treatment of rheumatic disorders: a systematic narrative review.Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases.Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab.
P2860

Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation

Item
http://www.wikidata.org/entity/Q34669637
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Adalimumab serum levels and an ...... upon treatment discontinuation
@ast
Adalimumab serum levels and an ...... upon treatment discontinuation
@en
Adalimumab serum levels and an ...... upon treatment discontinuation
@nl
type
label
Adalimumab serum levels and an ...... upon treatment discontinuation
@ast
Adalimumab serum levels and an ...... upon treatment discontinuation
@en
Adalimumab serum levels and an ...... upon treatment discontinuation
@nl
prefLabel
Adalimumab serum levels and an ...... upon treatment discontinuation
@ast
Adalimumab serum levels and an ...... upon treatment discontinuation
@en
Adalimumab serum levels and an ...... upon treatment discontinuation
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P5875
P6179
P698
P921
P932
P356
P1433
P1476
Adalimumab serum levels and an ...... upon treatment discontinuation
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P5875
P6179
P698
P921
P932